HIP1R acts as a tumor suppressor in gastric cancer by promoting cancer cell apoptosis and inhibiting migration and invasion through modulating Akt.


Journal

Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 12 01 2020
revised: 01 05 2020
accepted: 14 05 2020
pubmed: 18 6 2020
medline: 15 7 2021
entrez: 18 6 2020
Statut: ppublish

Résumé

Huntingtin-interacting protein 1-related (HIP1R) is a multi-domain gene that exerts many cellular functions including altering T cell-mediated cytotoxicity and controlling intracellular trafficking. However, its clinical significance and function in gastric cancer (GC) have not been described. The expression levels of HIP1R were tested by the transcriptional and translational expression analysis and immunohistochemistry (IHC) in matched adjacent non-tumorous vs tumor tissue specimens. The biological function of HIP1R on apoptosis, migration, and proliferation was evaluated by flow cytometry, Transwell, Cell Counting Kit-8 (CCK-8) assays, colony formation assays, and EdU labeling assays, respectively. We found downregulated HIP1R in GC compared with adjacent non-tumorous tissue, and HIP1R expression associated with N classification. We further found that the expression of HIP1R could induce apoptosis and inhibit proliferation, migration, invasion of GC cells, possibly through modulating Akt. Our data indicate that HIP1R may act as a potential diagnostic biomarker and a tumor suppressor gene in GC, potentially representing a novel therapeutic target for future GC treatment.

Sections du résumé

BACKGROUND BACKGROUND
Huntingtin-interacting protein 1-related (HIP1R) is a multi-domain gene that exerts many cellular functions including altering T cell-mediated cytotoxicity and controlling intracellular trafficking. However, its clinical significance and function in gastric cancer (GC) have not been described.
METHODS METHODS
The expression levels of HIP1R were tested by the transcriptional and translational expression analysis and immunohistochemistry (IHC) in matched adjacent non-tumorous vs tumor tissue specimens. The biological function of HIP1R on apoptosis, migration, and proliferation was evaluated by flow cytometry, Transwell, Cell Counting Kit-8 (CCK-8) assays, colony formation assays, and EdU labeling assays, respectively.
RESULTS RESULTS
We found downregulated HIP1R in GC compared with adjacent non-tumorous tissue, and HIP1R expression associated with N classification. We further found that the expression of HIP1R could induce apoptosis and inhibit proliferation, migration, invasion of GC cells, possibly through modulating Akt.
CONCLUSIONS CONCLUSIONS
Our data indicate that HIP1R may act as a potential diagnostic biomarker and a tumor suppressor gene in GC, potentially representing a novel therapeutic target for future GC treatment.

Identifiants

pubmed: 32548851
doi: 10.1002/jcla.23425
pmc: PMC7521271
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Biomarkers, Tumor 0
HIP1R protein, human 0
Microfilament Proteins 0
Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e23425

Subventions

Organisme : China Postdoctoral Science Foundation
ID : 2018M640267
Organisme : China Postdoctoral Science Foundation
ID : 2018M640268
Organisme : Xingliao Talents Program in Liaoning Province
ID : XLYC1807164
Organisme : Project of Science and Technology of Shenyang
ID : 18-014-4-07
Organisme : National Natural Science Foundation of China
ID : 81872031
Organisme : National Natural Science Foundation of China
ID : U1908207

Informations de copyright

© 2020 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.

Références

Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Biotechniques. 2004 Jan;36(1):98-105
pubmed: 14740491
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Cold Spring Harb Perspect Biol. 2013 May 01;5(5):a017459
pubmed: 23637288
Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):168-73
pubmed: 18165318
Cell Death Dis. 2019 Mar 8;10(3):230
pubmed: 30850586
Lab Invest. 2012 Jul;92(7):1045-57
pubmed: 22525425
Nat Rev Gastroenterol Hepatol. 2014 Nov;11(11):664-74
pubmed: 25134511
Exp Mol Pathol. 2015 Dec;99(3):537-45
pubmed: 26341140
J Clin Lab Anal. 2020 Sep;34(9):e23425
pubmed: 32548851
Leukemia. 2014 Feb;28(2):362-72
pubmed: 23884370
J Hum Genet. 1998;43(4):268-71
pubmed: 9852681
Cold Spring Harb Perspect Biol. 2013 Dec 01;5(12):a016949
pubmed: 24296170
Am J Physiol Gastrointest Liver Physiol. 2010 Dec;299(6):G1241-51
pubmed: 20813912
Nat Med. 1998 Jul;4(7):844-7
pubmed: 9662379
J Biol Chem. 2004 Apr 2;279(14):14294-306
pubmed: 14732715
Cancer Cell. 2003 May;3(5):471-82
pubmed: 12781365
Oncogene. 2016 Sep 8;35(36):4752-61
pubmed: 26898757
Cancer Res. 2007 Apr 15;67(8):3609-15
pubmed: 17440072
Sci Rep. 2017 Apr 28;7:45960
pubmed: 28452374
Hum Mol Genet. 2001 Aug 15;10(17):1807-17
pubmed: 11532990
Nat Chem Biol. 2019 Jan;15(1):42-50
pubmed: 30397328
Cancer Res. 1995 Jan 15;55(2):237-41
pubmed: 7812951
Am J Respir Crit Care Med. 2016 Apr 15;193(8):869-80
pubmed: 26595459
J Cell Biol. 1999 Dec 27;147(7):1503-18
pubmed: 10613908
Science. 1997 Jan 31;275(5300):665-8
pubmed: 9005852
J Clin Invest. 2008 Jul;118(7):2459-70
pubmed: 18535670
Exp Cell Res. 2011 Nov 15;317(19):2759-64
pubmed: 21907708
Nat Rev Cancer. 2008 Nov;8(11):835-50
pubmed: 18948996
J Cell Sci. 2003 Jun 15;116(Pt 12):2551-64
pubmed: 12734398
Histopathology. 2013 Jun;62(7):1038-48
pubmed: 23614500
J Pineal Res. 2012 Aug;53(1):77-90
pubmed: 22335196
BMB Rep. 2010 Dec;43(12):795-800
pubmed: 21189155
Cancer Res. 2007 Sep 15;67(18):8923-31
pubmed: 17875735
J Biol Chem. 2001 Oct 19;276(42):39271-6
pubmed: 11517213
Cell Physiol Biochem. 2009;23(1-3):43-52
pubmed: 19255499
J Cell Biol. 2004 Jun 21;165(6):781-8
pubmed: 15210728
Biochem Soc Trans. 2010 Feb;38(Pt 1):187-91
pubmed: 20074057
World J Surg Oncol. 2013 Jul 04;11:150
pubmed: 23822740
Mol Cell Biol. 2001 Nov;21(22):7796-806
pubmed: 11604514
Genetics. 2003 Dec;165(4):1661-74
pubmed: 14704157
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lancet. 2016 Nov 26;388(10060):2654-2664
pubmed: 27156933
J Cell Biol. 2001 Sep 17;154(6):1209-23
pubmed: 11564758
Nat Genet. 1997 May;16(1):44-53
pubmed: 9140394
Mol Cell Biol. 1997 Jan;17(1):338-44
pubmed: 8972214

Auteurs

Jinliang Zhu (J)

Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Department of Surgical Oncology and General Surgery, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang, China.
Department of Gastrointestinal Surgery, Shenyang Anorectal Hospital, Shenyang, China.

Xin Wang (X)

Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Department of Surgical Oncology and General Surgery, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang, China.

Huiyuan Guan (H)

Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Department of Surgical Oncology and General Surgery, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang, China.

Qiong Xiao (Q)

Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Department of Surgical Oncology and General Surgery, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang, China.

Zhonghua Wu (Z)

Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Department of Surgical Oncology and General Surgery, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang, China.

Jinxin Shi (J)

Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Department of Surgical Oncology and General Surgery, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang, China.

Fei Zhang (F)

Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Department of Surgical Oncology and General Surgery, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang, China.

Peng Gao (P)

Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Department of Surgical Oncology and General Surgery, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang, China.

Yongxi Song (Y)

Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Department of Surgical Oncology and General Surgery, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang, China.

Zhenning Wang (Z)

Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Department of Surgical Oncology and General Surgery, Ministry of Education, The First Affiliated Hospital of China Medical University, Shenyang, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH